Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients

Shashank Shekhar, Rahul Kumar, Nitish Rai, Vijay Kumar, Kusum Singh, Ashish Datt Upadhyay, Manjari Tripathi, Sadanand Dwivedi, Aparajit B Dey, Sharmistha Dey, Shashank Shekhar, Rahul Kumar, Nitish Rai, Vijay Kumar, Kusum Singh, Ashish Datt Upadhyay, Manjari Tripathi, Sadanand Dwivedi, Aparajit B Dey, Sharmistha Dey

Abstract

The elevated level of cerebrospinal fluid (CSF) Tau and phosphorylated Tau181 (p-Tau181) proteins are well established hallmarks of Alzheimer's disease (AD). Elevated level of p-Tau181 can differentiate AD from other neurodegenerative disease. However, the expression level of these proteins in serum of AD patient is not well set up. This study sought to evaluate the level of Tau and p-Tau181 in serum of AD, and mild cognitive impairment (MCI) patients for an alternative approach to establish protein-based markers by convenient way. Blood samples were collected from 39 AD patients, 37 MCI patients and 37 elderly individuals as controls. The levels of Tau and p-Tau181 in the serum of the different groups were measured by label free real time Surface Plasmon Resonance technology by using specific antibodies, and were further confirmed by the conventional western blot method. An appropriate statistical analysis, including Receiver Operating Characteristic (ROC), was performed. The concentrations of serum Tau and p-Tau181 were significantly higher (p<0.00001) in AD (Tau; 47.49±9.00ng/μL, p-Tau181; 0.161±0.04 ng/μL) compared to MCI (Tau; 39.26±7.78 ng/μL, p-Tau181; 0.135±0.02 ng/μL) and were further higher compared to elderly controls (Tau; 34.92±6.58 ng/μL, p-Tau181; 0.122±0.01 ng/ μL). A significant (p<0.0001) downhill correlation was found between Tau as well as p-Tau181 levels with HMSE and MoCA score. This study for the first time reports the concentration of Tau and p-Tau181 in serum of AD and MCI patients. The cutoff values of Tau and p-Tau181 of AD and MCI patients with sensitivity and specificity reveal that serum level of these proteins can be used as a predictive marker for AD and MCI.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Scatter graph showing the serum…
Fig 1. Scatter graph showing the serum level of Tau (A) and p-Tau181 (B) in AD, MCI and elderly control.
Fig 2. ROC analysis showing area under…
Fig 2. ROC analysis showing area under curve, threshold value with sensitivity and specificity, for Tau: (A) AD vs control (B) MCI vs control for p-Tau181: (C) AD vs control (D) MCI vs control.

References

    1. World Health Organization. Dementia: a Public Health Priority (World Health Organization, Geneva, 2012).
    1. Shaji KS, Jotheeswaran AT, Girish N, Srikala B, Amit D, Meera P, et al. (2010) Alzheimer’s & Related Disorders Society of India. The Dementia India Report: prevalence, impact, costs and services for Dementia: Executive Summary. ARDSI, New Delhi.
    1. Mark M, Amrita KC, Massimo SF, Xiaogang Z, Timothy RM, Linda HM, et al. (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nature medicine. 20: 415–418. 10.1038/nm.3466
    1. Blennow K, Hampel H, Weiner M, Zetterberg H. (2010)Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol 6: 131–144. 10.1038/nrneurol.2010.4
    1. Billingsley ML, Kincaid RL. (1997) "Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration". Biochem. J. 323: 577–91.
    1. Feijoo C, Campbell DG, Jakes R, Goedert M, Cuenda A. (2005) Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38δ at Thr50 promotes microtubule assembly. J Cell Sci 118: 397–408.
    1. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al.(2009) Cerebrospinal fluid βamyloid 42 and tau proteins as biomarkers of Alzheimer type pathologic changes in the brain. Arch.Neurol 66: 382–389. 10.1001/archneurol.2008.596
    1. Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. (2013) Plasma tau levels in Alzheimer’s disease. Alzheimer’s Research & Therapy 5:9
    1. Chiu MJ, Chen YF, Chen TF, Yang SY, Yang FP, Tseng TW, et al. (2014) Plasma Tau as a Window to the Brain—Negative Associations With Brain Volume and Memory Function in Mild Cognitive Impairment and Early Alzheimer’s Disease. Human Brain Mapping 35: 3132–3142. 10.1002/hbm.22390
    1. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. (2009) Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement GeriatrCognDisord 27: 458–464.
    1. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 129: 3042–50
    1. Ganguli M, Ratcliff G, Chandra V, Sharma S, Gilby J, Rajesh P, et al. (1995)A Hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in India. International Journal of Geriatric Psychiatry 10: 367–377.
    1. O’Caoimh R, Timmons S, Molloy DW. (2016) Screening for Mild Cognitive Impairment: Comparison of “MCI Specific” Screening Instruments. Journal of Alzheimer’s Disease, (Preprint), 1–11.
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Emanuel MS. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–944.
    1. Michael CI. (2004) Biomarkers of Alzheimer Disease in Plasma. NeuroRx 1: 226–234.
    1. Cummings JL. (2011) Biomarkers in Alzheimer’s disease drug development. Alzheimer’s & Dementia 7: e13–44.
    1. Billingsley ML, Kincaid RL. (1997) Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 323: 577–591.
    1. Morris M, Maeda S, Vossel K, Mucke L. (2011) The Many Faces of Tau. Neuron 70: 410–426. 10.1016/j.neuron.2011.04.009
    1. Brunden KR, Trojanowski JQ, Lee VM. (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8: 783–793. 10.1038/nrd2959
    1. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. (2010) Cerebrospinal fluid total tau as a marker of Alzheimer’s disease intensity. Int J Geriatr Psychiatry 25: 403–410 10.1002/gps.2353
    1. Hampel H, Bürger K, Pruessner JC, Zinkowski R, DeBernardis J. (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 62: 770–773.
    1. Kandimalla RJ, Prabhakar S, Wani WY, Kaushal A, Gupta N, Deep RS, et al. (2013) CSF p-Tau levels in the prediction of Alzheimer's disease. Biol Open 2: 1119–1124. 10.1242/bio.20135447
    1. Kumar R, Chaterjee P, Sharma PK, Singh AK, Gupta A, Gill K, et al. (2013) Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer’s Disease. PLoS ONE 8(4): e61560 10.1371/journal.pone.0061560

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel